Herceptin
Named-patient access overview. Herceptin is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Herceptin (trastuzumab) is a humanised anti-HER2 monoclonal antibody developed by Genentech and Roche. The US Food and Drug Administration first approved Herceptin in September 1998 for HER2-overexpressing metastatic breast cancer, with subsequent expanded indications covering adjuvant and neoadjuvant HER2-positive early breast cancer and HER2-overexpressing metastatic gastric or gastro-oesophageal junction adenocarcinoma. Standard dosing is intravenous, given as a loading dose followed by maintenance every one or three weeks depending on regimen. Treatment is administered in an oncology infusion centre under medical oncology supervision, with baseline and serial cardiac function monitoring throughout the treatment course.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Herceptin
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Herceptin is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Herceptin in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Herceptin
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.